Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Hudson finds solution for legacy sites which have dogged predecessors.
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies